Understanding The EU Regulatory Landscape For Cell And Gene Therapies

For US-based cell and gene therapy developers, achieving EU approval isn't simply a matter of transposing an FDA strategy across the Atlantic; it demands a fundamentally different mindset. The EU regulatory environment is shaped by written-first scientific dialogue, a pharmaceutical legislation overhaul that will restructure how advanced therapy medicinal products are reviewed, and a narrower definition of gene therapy that may not map cleanly to US classifications. Each of these factors carries real consequences for development timelines, submission strategy, and market access.

Companies that treat EU regulatory engagement as an afterthought risk costly missteps during a period when the rules themselves are actively evolving. This article breaks down five of the most pressing challenges currently facing ATMP developers in the EU and the practical considerations that can help biopharma teams navigate them with confidence. Read on to build a stronger foundation for your EU regulatory strategy.